Role of PAI-1 in hepatic steatosis and dyslipidemia
Abstract Plasminogen activator inhibitor 1 (PAI-1) is a functional biomarker of the metabolic syndrome. Previous studies have demonstrated that PAI-1 is a mechanistic contributor to several elements of the syndrome, including obesity, hypertension and insulin resistance. Here we show that PAI-1 is a...
Guardado en:
Autores principales: | Joshua A. Levine, Carlota Oleaga, Mesut Eren, Ansel P. Amaral, Meng Shang, Elizabeth Lux, Sadiya S. Khan, Sanjiv J. Shah, Yasuhiro Omura, Nathalie Pamir, Joshua Hay, Grant Barish, Toshio Miyata, Hagai Tavori, Sergio Fazio, Douglas E. Vaughan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/70f544abac804254b08f94ba760c8b5e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Hyperglycemia-stimulating diet induces liver steatosis in sheep
por: Mugagga Kalyesubula, et al.
Publicado: (2020) -
Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia
por: Hirotaka Fukami, et al.
Publicado: (2021) -
Dyslipidemias in diabetes
por: HELENA W RODBARD
Publicado: (2004) -
Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
por: Wah-Kheong Chan, et al.
Publicado: (2014) -
Diabetes and dyslipidemia: characterizing lipoprotein metabolism
por: Tomkin GH, et al.
Publicado: (2017)